Receptors, Vascular Endothelial Growth Factor
"Receptors, Vascular Endothelial Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels.
Descriptor ID |
D040262
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.950 D12.776.543.750.630.750 D12.776.543.750.750.400.910
|
Concept/Terms |
Receptors, Vascular Endothelial Growth Factor- Receptors, Vascular Endothelial Growth Factor
- Receptor, Vascular Endothelial Cell Growth Factor
- Receptor, Vascular Permeability Factor
- VEGF Receptors
- Receptors, VEGF
- Vascular Endothelial Cell Growth Factor Receptor
- VPF Receptor
- Vascular Endothelial Growth Factor Receptor
- VEGF Receptor
- Vascular Permeability Factor Receptor
|
Below are MeSH descriptors whose meaning is more general than "Receptors, Vascular Endothelial Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Vascular Endothelial Growth Factor".
This graph shows the total number of publications written about "Receptors, Vascular Endothelial Growth Factor" by people in this website by year, and whether "Receptors, Vascular Endothelial Growth Factor" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 1 | 1 | 1996 | 0 | 1 | 1 | 1999 | 0 | 1 | 1 | 2000 | 0 | 2 | 2 | 2001 | 0 | 1 | 1 | 2002 | 0 | 4 | 4 | 2003 | 3 | 3 | 6 | 2004 | 4 | 1 | 5 | 2005 | 2 | 3 | 5 | 2006 | 2 | 5 | 7 | 2007 | 8 | 2 | 10 | 2008 | 0 | 1 | 1 | 2009 | 1 | 3 | 4 | 2010 | 1 | 1 | 2 | 2012 | 0 | 2 | 2 | 2013 | 1 | 3 | 4 | 2015 | 1 | 1 | 2 | 2016 | 1 | 1 | 2 | 2020 | 0 | 1 | 1 | 2022 | 0 | 1 | 1 | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Receptors, Vascular Endothelial Growth Factor" by people in Profiles.
-
Capdevila J, Krajewska J, Hernando J, Robinson B, Sherman SI, Jarzab B, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Williamson D, Levytskyy R, Oliver J, Keam B, Brose MS. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 Mar; 34(3):347-359.
-
Jones AA, Morgenstern JL, Mandair D, Pedler MG, Olson JL. EFFICACY OF INTRAVITREAL AFLIBERCEPT INJECTIONS IN THE TREATMENT OF IDIOPATHIC RETINAL VASCULITIS, ANEURYSMS, AND NEURORETINITIS SYNDROME. Retin Cases Brief Rep. 2022 Jul 01; 16(4):515-519.
-
Le Cras TD, Abman SH. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema. Am J Respir Crit Care Med. 2020 03 01; 201(5):620-621.
-
Bedoya A, Glisinski K, Clarke J, Lind RN, Buckley CE, Shofer S. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases. Am J Case Rep. 2017 Jul 31; 18:842-846.
-
Kalpathy-Cramer J, Chandra V, Da X, Ou Y, Emblem KE, Muzikansky A, Cai X, Douw L, Evans JG, Dietrich J, Chi AS, Wen PY, Stufflebeam S, Rosen B, Duda DG, Jain RK, Batchelor TT, Gerstner ER. Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma. J Neurooncol. 2017 02; 131(3):603-610.
-
Atienzar-Aroca S, Flores-Bellver M, Serrano-Heras G, Martinez-Gil N, Barcia JM, Aparicio S, Perez-Cremades D, Garcia-Verdugo JM, Diaz-Llopis M, Romero FJ, Sancho-Pelluz J. Oxidative stress in retinal pigment epithelium cells increases exosome secretion and promotes angiogenesis in endothelial cells. J Cell Mol Med. 2016 08; 20(8):1457-66.
-
Graham BB, Kumar R, Mickael C, Sanders L, Gebreab L, Huber KM, Perez M, Smith-Jones P, Serkova NJ, Tuder RM. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am J Physiol Lung Cell Mol Physiol. 2015 Sep 01; 309(5):L435-40.
-
SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015 Dec; 43(9):803-7.
-
Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, Farkas L, Cho SX, Zepp JA, Azam T, Dinkel H, Palmer BE, Boisvert WA, Cool CD, Taraseviciene-Stewart L, Heinhuis B, Joosten LA, Dinarello CA, Voelkel NF, Nold MF. IL-32 promotes angiogenesis. J Immunol. 2014 Jan 15; 192(2):589-602.
-
Velez-Montoya R, Oliver SC, Olson JL, Fine SL, Mandava N, Quiroz-Mercado H. Current knowledge and trends in age-related macular degeneration: today's and future treatments. Retina. 2013 Sep; 33(8):1487-502.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|